NBIX 13F Hedge Fund and Asset Management Owners

Data as of 2020-11-22
Market Cap	8.315 Billion	Shares Outstanding	93.429 Million	Avg 30-day Volume	958.373 Thousand
P/E Ratio	94.7	Dividend Yield		EPS	0.94
Price/Sales	7.98	Price cash flow ratio	36.0	Price free cash flow ratio	35.7
Book Value	8.61	Price to Tangible Book	10.34	Alpha	0.01
Short Interest Ratio		% Short Interest to Float		R-squared	0.149326
BETA	1.13664	52-week High/Low	136.265 / 72.14	Stddev	0.123953

Q3 2020	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change
In top 10:	6	8	-25.0%	4 (0.26%)	5 (0.32%)	-20.0%
Funds Holding:	397	408	-2.7%	118 (7.76%)	107 (6.94%)	10.28%
13F shares:	88.621 Million	90.366 Million	-1.93%	17.859 Million	17.647 Million	1.2%
% Ownership	95.0306	96.9021	-1.93%	19.151	18.9237	1.2%
New Positions:	63	86	-26.74%	27	20	35.0%
Increased Positions	184	169	8.88%	49	39	25.64%
Closed Positions	67	36	86.11%	16	12	33.33%
Reduced Positions	106	109	-2.75%	33	41	-19.51%
Total Calls	400.112 Thousand	647.493 Thousand	-38.21%	149.4 Thousand	184.7 Thousand	-19.11%
Total Puts	1.366 Million	655.56 Thousand	108.42%	379.8 Thousand	115.4 Thousand	229.12%
PUT/CALL Ratio	3.41	1.01	237.62%	2.54	0.62	309.68%
¹ hedge funds and active managers as identified by whalewisdom.com through public filings.

Funds Holding NBIX (via 13F filings)

Quarter to view: Refresh Download CSV Download Excel (.xlsx) Download TSV

Market Value:

Ranking:

% of portfolio

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NBIX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

44.3 Thousand total shares from 11 transactions

Exercise Derivative Conversion (M)

20.6 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name	Type	Last Reported Shares Held	Last Reported Date	Filings in past year
GORMAN KEVIN CHARLES CHIEF EXECUTIVE OFFICER	Officer Director	441,071	2020-11-12	5
BOZIGIAN HAIG P. CHIEF DEVELOPMENT OFFICER	Officer	152,694	2020-11-12	6
GRIGORIADIS DIMITRI E. CHIEF RESEARCH OFFICER	Officer	81,624	2020-11-12	8
GANO KYLE CHIEF BUSINESS DEVELOPMENT OFF	Officer	98,028	2020-11-12	5
LLOYD-SMITH MALCOLM CHIEF REGULATORY OFFICER	Officer	29,002	2020-11-12	5
LIPPOLDT DARIN CHIEF LEGAL OFFICER	Officer	30,082	2020-11-12	8
BENEVICH ERIC CHIEF COMMERCIAL OFFICER	Officer	17,405	2020-11-12	7
ABERNETHY MATT CHIEF FINANCIAL OFFICER	Officer	10,014	2020-11-12	7
ROBERTS EIRY CHIEF MEDICAL OFFICER	Officer	13,477	2020-11-12	7
COOKE JULIE CHIEF HUMAN RESOURCES OFFICER	Officer	11,580	2020-11-12	6
RASTETTER WILLIAM H	Director	0	2020-05-19	1
SHERWIN STEPHEN A	Director	0	2020-05-19	2
POPS RICHARD F	Director	0	2020-05-19	1
LYONS GARY A	Director	0	2020-05-19	1
MORROW GEORGE J	Director	0	2020-05-19	1
NORWALK LESLIE V	Director	0	2020-05-19	1
SHARP SHALINI	Director	0	2020-02-01	2
SANDROCK ALFRED	Director	0	2019-05-22	0
NEVINNY CORINNE H	Director	0	2018-05-24	0
OBRIEN CHRISTOPHER FLINT FORMER CHIEF MEDICAL OFFICER	Officer	55,946	2018-02-05	0
MOLLICA JOSEPH A	Director	0	2017-05-22	0
COUGHLIN TIMOTHY P CHIEF FINANCIAL OFFICER	Officer	137,961	2017-02-06	0
GROS DAVID-ALEXANDRE C PRESIDENT & COO	Officer	0	2017-02-06	0
MITCHELL W THOMAS	Director	1,000	2015-06-23	0
NEUROCRINE BIOSCIENCES INC	Director	16,030	2015-04-07	0
BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BIOTECHNOLOGY VALUE FUND II LP BVF INVESTMENTS LLC BVF INC/IL LAMPERT MARK N	SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES	No longer subject to file	2012-02-09	0
VALEUR JENSEN MARGARET E EVP AND GENERAL COUNSEL	Officer	0	2011-08-31	0
VALE WYLIE W	Director	0	2011-05-25	0
VENROCK HEALTHCARE CAPITAL PARTNERS LP VHCP CO-INVESTMENT HOLDINGS, LLC HOVE ANDERS D ROBERTS BRYAN E VHCP MANAGEMENT, LLC	10% Owner	4,784,689	2009-12-22	0
ROBERTS BRYAN E	10% Owner	4,784,689	2009-12-22	0
HOVE ANDERS D	10% Owner	4,784,689	2009-12-22	0
BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BIOTECHNOLOGY VALUE FUND II LP BVF INVESTMENTS LLC BVF INC/IL	10% Owner INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER	5,946,547	2009-01-22	0

Insider Transactions Last 60 Days

Reporting Owners	Filing Date	Trans Date	Trans Code	Shares	Share Price	Acquired Disposed	Shares Owned after	D/I	10b5	Perf 1d*	Perf 5d*	Max Gain	Max Gain Days	Max Loss	Max Loss Days
ROBERTS EIRY - Officer CHIEF MEDICAL OFFICER	2020-11-16 18:23:59 -0500	2020-11-12	S	2,257	$90.74	d	13,477	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2020-11-16 18:11:48 -0500	2020-11-12	S	2,257	$90.73	d	98,028	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER	2020-11-16 18:20:17 -0500	2020-11-12	S	2,257	$90.72	d	30,082	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2020-11-16 18:27:23 -0500	2020-11-12	S	2,257	$90.71	d	17,405	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2020-11-16 18:16:04 -0500	2020-11-12	S	3,390	$90.78	d	441,071	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
ABERNETHY MATT - Officer CHIEF FINANCIAL OFFICER	2020-11-16 18:02:09 -0500	2020-11-12	S	2,257	$90.74	d	10,014	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER	2020-11-16 18:21:47 -0500	2020-11-12	S	2,257	$90.73	d	29,002	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
COOKE JULIE - Officer CHIEF HUMAN RESOURCES OFFICER	2020-11-16 18:10:20 -0500	2020-11-12	S	2,257	$90.73	d	11,580	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2020-11-16 18:19:03 -0500	2020-11-12	S	2,257	$90.73	d	81,624	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2020-11-16 18:08:41 -0500	2020-11-12	S	2,257	$90.74	d	152,694	direct	yes	-5.2752	4.4251	4.4251	6	-5.2752	2
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2020-11-04 18:09:09 -0500	2020-11-02	M	20,595	$35.99	a	35,969	direct		-3.9673	-9.8385	2.4821	3	-12.6994	4
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2020-11-04 18:09:09 -0500	2020-11-02	M	20,595	$35.99	d	7,775	direct
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2020-11-04 18:09:09 -0500	2020-11-02	S	20,595	$96.53	d	15,374	direct	yes	-3.9673	-9.8385	2.4821	3	-12.6994	4

* -

Transaction Code Definitions
Code	Definition
A	Grant, award or other acquisition pursuant to Rule 16b-3(d)
C	Conversion of derivative security
D	Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E	Expiration of short derivative position
F	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G	Bona fide gift
H	Expiration (or cancellation) of long derivative position with value received
I	Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J	Other acquisition or disposition
L	Small acquisition under Rule 16a-6
M	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O	Exercise of out-of-the-money derivative security
P	Open market or private purchase of non-derivative or derivative security
S	Open market or private sale of non-derivative or derivative security
U	Disposition pursuant to a tender of shares in a change of control transaction
W	Acquisition or disposition by will or the laws of descent and distribution
X	Exercise of in-the-money or at-the-money derivative security
Z	Deposit into or withdrawal from voting trust

Neurocrine Biosciences Inc. Chart by YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Neurocrine Biosciences Inc. (NBIX)

WhaleWisdom Alpha

Our Other Reporting & Analysis